Document is current

Any future updates will be listed below

CD40-Liganden-Blockade: Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Crossref DOI link: https://doi.org/10.1007/s15005-025-4389-1

Published Online: 2025-06-24

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark